Thursday, June 10

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Hall F

EUROPEAN WORKING GROUP FOR ADULT ALL (EWALL)

Chair: D Hoelzer (J.W.Goethe University Hospital, Frankfurt, Germany)
N Gökbuget (J.W.Goethe University Hospital, Frankfurt, Germany)

• THE GIMEMA STRATEGY FOR PH+ ALL

  R Foà (GIMEMA) (University ‘La Sapienza’, Rome, Italy)
  G Meloni (GIMEMA) (University ‘La Sapienza’, Rome, Italy)

• UKALL12 FINAL ANALYSIS ON IMATINIB IN PH+ ALL

  A Fielding (NCRI) (University College London Medical School, London, United Kingdom)

• INTERIM RESULTS OF THE NEW MRD AND RISK ORIENTED STUDY 10/07

  R Bassan (NILG) (Ospedali Riuniti, Bergamo, Italy)

• MRD-BASED TREATMENT IN GMALL STUDY 07/200375

  N Gökbuget (GMALL) (J.W.Goethe University Hospital, Frankfurt, Germany)

• RESULTS OF THE GRAALL STUDIES 2003 AND 2005 IN PH-NEGATIVE ALL

  H Dombret (GRAALL) (Hôpital Saint-Louis, Paris, France)

• RESULTS OF SPECIFIC IMMUNOCHEMOTHERAPY IN HIV-RELATED BURKITT'S LEUKEMIA AND LYMPHOMA

  J Ribera (PETHEMA) (ICO-Hospital Universitari Germans Trias i Pujol, Badalona, Spain)

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Hall G

EUROPEAN RESEARCH INITIATIVE ON CLL

Chair: P Dreger (Universitätsklinikum Heidelberg, Heidelberg, Germany)
E Kimby (Karolinska Institute, Stockholm, Sweden)
E Montserrat (Hospital Clinic, Barcelona, Spain)

• AUTOLOGOUS STEM CELL TRANSPLANTATION IN CLL - ANY PERSPECTIVE IN 2010?

  M Michallet (Hopital Edouard Herriot, Lyon, France)

• INDIVIDUALIZED / RISK-ADAPTED ALLO-SCT FOR CLL - WHERE DO WE STAND?

  M Ritgen (University Hospital Schleswig-Holstein Campus Kiel, Kiel, Germany)

• FIVE YEARS EBMT/ERIC CLL TRANSPLANT CONSENSUS: TIME FOR AN UPDATE?

  P Dreger (Universitätsklinikum Heidelberg, Heidelberg, Germany)

• ALLOGENEIC STEM CELL TRANSPLANTATION: A CURATIVE APPROACH FOR T PLL?

  C Dearden (The Royal Marsden Hospital, Sutton, United Kingdom)
  

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Hall M

EUROFLOW

Chair: J van Dongen (Erasmus Medical Center, Rotterdam, The Netherlands)
A Orfao (University of Salamanca, Salamanca, Spain)

• EUROFLOW 2010

  J van Dongen (Erasmus Medical Center, Rotterdam, The Netherlands)

• SOFTWARE-GUIDED DATA ANALYSIS AND INTERPRETATION

  M Martin (Cytognos S.L., Salamanca, Spain)

• HOW TO ANALYZE A PATIENT WITH LYMPHOCYTOSIS

  P Lucio (Instituto Portugués de Oncologia, Lisbon, Portugal)

• HOW TO ANALYSE A PATIENT SUSPECTED OF ACUTE LEUKEMIA

  A Orfao (University of Salamanca Salamanca, Spain)

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Hall L

LEUKEMIC STEM CELLS

Chair: D Bonnet (Cancer Research UK, London Research Institute, London, United Kingdom) C Chomienne (Hôpital Saint Louis, Paris, France)
P Valent (Medical University Vienna, Vienna, Austria)

• CANCER STEM CELL NETWORKING IN EUROPE FOR RESEARCH AND TRAINING

  C Chomienne (Hôpital Saint Louis, Paris, France)

• TECHNIQUES TO STUDY STEM CELL QUIESCENCE

  A Trumpp (DKFZ German Cancer Research Center, Heidelberg, Germany)

• REGULATORS OF ADULT HEMATOPOIETIC STEM CELLS

  T Enver (John Radcliffe Hospital, MRC Molecular Haematology Unit, Oxford, United Kingdom)

• PROPOSED ANIMAL MODELS FOR LSC DETECTION AND TARGETING

  D Bonnet (Cancer Research UK, London Research Institute, London, United Kingdom)

• DEFINITION, PURIFICATION AND DRUG TARGETING OF LSC

  P Valent (Medical University Vienna, Vienna, Austria)

• CONCLUDING REMARKS

  D Bonnet (Cancer Research UK, London Research Institute, London, United Kingdom)
  P Valent (Medical University Vienna, Vienna, Austria)

SCIENTIFIC WORKING GROUP
18:30 – 20:00, Hall N

THROMBOCYTOPENIAS

Chair: N Cooper (Imperial Health Care NHS Trust, London, United Kingdom)

• USING THROMBOPOIETIN AGENTS IN CLINICAL PRACTISE, POST LICENSING TBC

  M Rummel (Hospital of the Justus-Liebig University, Gießen, Germany)

• LONG TERM FOLLOW UP OF RITUXIMAB

  J Bussel (Cornell medical School, New York, USA)

• IS SPLENECTOMY STILL INDICATED FOR ITP?

  B Godeau (Hôpital Henri Mondor, Créteil, France)

• THE EFFECT OF TPO AGENTS ON REGULATORY T CELLS IN ITP

  K Yazdanbakhsh (New York Blood Center, New York, USA)

• AN UPDATE OF THE BLEEDING SCORE IN PATIENTS WITH ITP

  M Michel (Hôpital Henri Mondor, Créteil, France)

• THROMBOSIS IN ITP

  F Rodeghiero (San Bortolo Hospital, Vicenza, Italy)

• MRI SCANS FOR ASSESSMENT OF BLEEDING AND FAILURE OF T EFFECTOR CELLS TO DIE IN PATIENTS WITH ITP

  N Cooper (Imperial Health Care NHS Trust, London, United Kingdom)

SCIENTIFIC WORKING GROUP
18:30 – 20:00, Hall K

MYELOPROLIFERATIVE DISORDERS

Chair: H Pahl (University Hospital Freiburg, Freiburg, Germany)

• ANTI-INFLAMMATION HEPATOCYTE GROWTH FACTOR AND INTERLEUKIN-11 ARE OVER-EXPRESSED IN POLYCYTHEMIA VERA AND CONTRIBUTE TO THE GROWTH OF CLONAL ERYTHROBLASTS INDEPENDENTLY OF JAK2V617F

  M Boissinot (INSERM U892, Nantes Cedex 1, France)
  Mentor: S Hermouet (INSERM U892, Nantes Cedex 1, France)
  

• OVEREXPRESSION OF TRANSCRIPTION FACTOR NF-E2 IN VIVO, A NOVEL MURINE MODEL OF MPNS

  K Kaufmann (University Hospital Freiburg, Freiburg, Germany)
  Mentor: H Pahl (University Hospital Freiburg, Freiburg, Germany)

• MPN/MPNR EURONET: A EUROPEAN, EU SPONSORED NETWORK OF EXPERTS ON THE MOLECULAR DIAGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS (MPN) AND MPN-RELATED CONGENITAL DISEASES (MPNR). COST ACTION BM902

  S Hermouet (INSERM U892, Nantes Cedex 1, France)
  WP1: E Lippert (Laboratoire Universitaire d'Hématologie, Bordeaux, France)
  WP2: J Schwarz (Institute of Hematology and Blood Transfusion, Prague, Czech Republic)
  WP3: MF Mc Mullin (Queen's University, Belfast, Northern Ireland, UK)
  WP4: H Pahl (University Hospital Freiburg, Freiburg, Germany)
  

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Room 61

EUROPEAN STUDY GROUP ON MRD DETECTION IN ALL

Chair: T Raff (University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany)

• MRD-BASED TREATMENT IN FUTURE EUROPEAN LYMPHOMA TRIALS

  M Ladetto (Università di Torino, Torino, Italy)

• MRD IN ADULT ALL STUDIES - EXPERIENCE AND DEVELOPMENTS

  T Raff (University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany)

• EXTENDED MRD-KINETICS IN CHILDREN WITH HIGH-RISK ALL TREATED IN THE ALL-BFM 2000 TRIAL

  A Schrauder (University Hospital Schleswig-Holstein, Campus Kiel, Kiel,
  Germany)

• STANDARDIZED MRD QUANTIFICATION IN ALL TRIALS - CONSENSUS GUIDELINES OF EUROPEAN ALL STUDY GROUPS

  M Brüggeman (University Hospital Schleswig-Holstein, Campus Kiel,
  Kiel, Germany)

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Room 62

MYELODYSPLASTIC SYNDROMES

Chair: E Hellström-Lindberg (Karolinska University Hospital Huddinge, Stockholm, Sweden)
P Fenaux (Hôpital Avicenne/ Paris 13 University, Bobigny, France)

ADVANCES IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND OTHER MIXED MYELODYSPLASTIC MYELOPROLIFERATIVE DISORDERS (MDS/MPN)

• NEW WHO CLASSIFICATION OF MDS/MPN AND NEW FINDINGS IN RARS-T

  L Malcovati (University of Pavia, S. Matteo Hospital, Pavia, Italy)

• MOLECULAR BIOLOGY OF CMML

  A Mohammedali (King's College Hospital, London, United Kingdom)

• CELL BIOLOGY IN CMML

  N Droin (Institut Gustave Roussy, Villejuif, France)

• TREATMENT OF CMML

  T Braun (Hôpital Avicenne/ Paris 13 University, Bobigny, France)

• DNA METHYLATION AS MOLECULAR MARKER OF PROGNOSIS IN JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML)

  C Flotho ( University of Freiburg, Freiburg, Germany)

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Room 63

CHRONIC MYELOID LEUKEMIA

Chair: J Goldman (Imperial College London, London, United Kingdom)

• HETEROGENEITY IN THE CML STEM CELL COMPARTMENT

  R Lemoli (Institute of Hematology Seràgnoli, Bologna, Italy)

• CLINICAL APPLICATIONS OF GENE EXPRESSION PROFILING

  V Oehler (Fred Hutchinson Cancer Research Center, Seattle, USA)

• LESSONS FROM GENOMIC PCR FOR BCR-ABL1

  J Melo (University of Adelaide, Adelaide, Australia)

• MIR328 IN CML

  Danilo Perrotti (The Ohio State University, Columbus, USA)

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Room 64

MULTIPLE MYELOMA

Chair: P Sonneveld (Erasmus Medical Center and University, Rotterdam, The Netherlands)

• THE EU INTERGROUP TRIAL IN MULTIPLE MYELOMA

  P Sonneveld (Erasmus Medical Center and University, Rotterdam, The Netherlands)
  A Palumbo (Università di Torino, AOU S. Giovanni Battista, Turin, Italy)

• REPORT FROM THE EUROPEAN WORKSHOP ON FISH

  F Ross (University of Southampton, Salisbury, United Kingdom)
  H Avet-Loiseau (University Hospital Nantes, Nantes, France)

• CLINICAL IMPACT OF MULTIPARAMETRIC FLOW CYTOMETRY

  HE Johnsen (Aalborg Hospital, Aalborg, Denmark)
  A Orfao (University of Salamanca Salamanca, Spain)

• CURRENT STATUS OF MOLECULAR STUDIES IN CLINICAL TRIALS

  G Morgan (The Instittue of Cancer Research & The Royal Marsden
  NHS Foundation Trust, London, United Kingdom)
  M Boegsted (Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark)

• DRUG INDUCED TOXICITY AND SNP ANALYSIS

  D Johnson (Institute of Cancer Research, London, United Kingdom)
  P Sonneveld (Erasmus Medical Center and University, Rotterdam, The Netherlands)

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Room 65

GRANULOCYTE AND MONOCYTE DISORDERS

Chair: H Papadaki (University of Crete - School of Medicine, Heraklion, Greece)

• IS THERE A ROLE FOR PEG FILGRASTIM IN THE TREATMENT OF SCN?

  C Doufour (G. Gaslini Children's Hospital, Genova, Italy)

• LATE ONSET NEUTROPENIA (LON) ASSOCIATED WITH RITUXIMAB TREATMENT

  A. PATHOPHYSIOLOGIC MECHANISMS
  K Stamatopoulos (George Papanikolaou Hospital, Thessaloniki, Greece)
  B. INCIDENCE AND OUTCOME IN LYMPHOPROLIFERATIVE AND RHEUMATOLOGIC DISEASES
  D Tesfa (Karolinska Institutet at Karolinska University Hospital Huddinge, Sweden)

• NOVEL ASPECTS ON NEUTROPHIL-ENDOTHELIAL CELL INTERACTIONS

  J Palmblad (Karolinska Institutet at Karolinska University Hospital Huddinge, Sweden)
  

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Room 66

QUALITY OF LIFE AND SYMPTOMS

Chair: A Novik (National Medical Surgical Center, Moscow, Russia)

• QUALITY OF LIFE ISSUES IN PATIENTS WITH MULTIPLE MYELOMA - THE PATIENTS VOICE

  A Waldmann (Myeloma Euronet, Rüsselsheim, Germany)

• HEALTH RELATED QUALITY OF LIFE IN MULTIPLE MYELOMA PATIENTS - A NORDIC EXPERIENCE

  N Gulbrandsen (Oslo Universitetssykehus, Ullevål, Oslo, Norway)
  

• METHODOLOGICAL ASPECTS OF QUALITY OF LIFE AND SYMPTOM ASSESSMENT IN PATIENTS WITH HEMATOLOGICAL DISORDERS

  T Ionova (National Medical Surgical Center, Saint-Petersburg, Russia)

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Room 67

PHARMACOKINETIC, PHARMACOGENETIC & PHARMACODYNAMICS

Chair: M Hassan (Karolinska Institutet, Stockholm, Sweden)

• PRODUCTION OF IL10 AND ERYTHROPOITIN SENSITIVITY IN END STAGE RENAL DISEASE ON REGULAR HEMODIALYSIS

  A Fadia (Suez Canal University, Ismailia, Egypt)

• CLINICAL APPLICATION OF RADIO-LABELED RITUXIMAB; FEASIBILITY AND PITFALLS

  J Baars (Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek
  Ziekenhuis, Amsterdam, The Netherlands)

• ANTI-ANGIOGENIC EFFECT OF RESVERATROL AND CURCUMIN THROUGH THE INHIBITION OF MICROVESSEL DENSITY, VEGF AND ITS RECEPTOR VEGFR-2 (FLK-1) IN EHRLICH ASCITES CARCINOMA-BEARING MICE

  M El-Azab (Suez Canal University, Ismailia, Egypt)

• RELIABILITY OF LIMITED SAMPLING METHODS FOR CALCULATING AUC, TESTING A MATHEMATICAL MODEL USING CLINICAL DATA

  F Sjöö (Karolinska Institutet, Stockholm, Sweden)

• THIOPURINES: FACTORS INFLUENCING TOXICITY AND RESPONSE

  F Albertioni (Karolinska Hospital, Stockholm, Sweden)

SCIENTIFIC WORKING GROUP

18:30 – 20:00, Room 68

RED CELL METABOLISM AND ITS DISORDERS

Chair: MD Cappellini (Fondazione Policlinico IRCCS- University of Milan,
Milan, Italy)

• WELCOME AND UPDATE

  MD Cappellini (Fondazione Policlinico IRCCS- University of Milan, Milan, Italy)
  

• CONTROL OF FETAL HEMOGLOBIN: NEW INSIGHTS EMERGING FROM GENOMICS AND CLINICAL IMPLICATIONS

  SL Thein (Kings College Medical School, London, United Kingdom)
  

• COGENITAL DYSERYTHROPOIETIC ANEMIA TYPE II: FROM CLINICS TO MOLECULAR GENETIC

  A Iolascon (Ceinge - University of Naples, Naples, Italy)
  

• HOW ENERCA WORKS IN CLINICAL PRACTICE

  JL Vives Corrons (Red Cell Pathology Unit- University of Barcelona,
  Barcelona, Spain)
  

• DISCUSSION AND CONCLUSION

  C Beaumont (INSERM U773 -CRB3, Paris, France)